NANG KUANG PHARMACEUTICAL CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 1963-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.nangkuang.com.tw
Clinical Trials
7
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (42.9%)Phase 1
2 (28.6%)Phase 2
2 (28.6%)A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Pain, Postoperative
- Interventions
- Drug: ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05588557
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei city, Taiwan
A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04515953
- Locations
- 🇨🇳
Nang Kuang Pharmaceutical Co., LTD, Tainan City, Taiwan (台灣), Taiwan
Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02074267
- Locations
- 🇨🇳
Nang Kuang Pharmaceutical Co., LTD, Tainan, Taiwan
A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus
Phase 2
Terminated
- Conditions
- Localized Squamous Cell Carcinoma of the Esophagus
- Interventions
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02017600
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2
Terminated
- Conditions
- Neoplasms, Head and NeckCancer of the Head and Neck
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT01370876
- Locations
- 🇨🇳
Taipei Mackay Memorial Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- Next
News
No news found